IJCRR Section: Healthcare ISI Impact Factor (2019-20): 1.628 IC Value (2019): 90.81 SJIF (2020) = 7.893 Copyright@IJCRR ABSTRACT The origin of Severe Acute Respiratory Syndrome Coronavirus -2 [SARS CoV-2] from Wuhan city, China advanced to the catastrophic pandemic. There are attempts universally to gear up the potential therapeutic line in the treatment of COVID-19. The current management for COVID-19 is leaning towards the repurposing of drugs based on preceding outbreak data [SARS 2002-2003,

more »

... MERS-2012 and structural organization and genomics of the coronavirus. Unfortunately, no specific therapy is available to treat coronavirus infection amidst this emergency. Antibody improvement is a key element for decreasing mortality related to viral diseases. Viral vaccines have to be immunogenic, safe, efficacious and suitable to induce long-lasting immunity. Studies are being expedited right now in the development of a vaccine for coronavirus globally. India with a dense population and enormous resources related to pharmaceuticals can be one of the bulk manufacturers of Coronavirus vaccines. This article focuses on the outline of therapeutic options, vaccine development strategy and highlights the current status of vaccines trials in India.